E
Eric J. Allenspach
Researcher at University of Washington
Publications - 45
Citations - 2972
Eric J. Allenspach is an academic researcher from University of Washington. The author has contributed to research in topics: Immunology & Immune system. The author has an hindex of 19, co-authored 36 publications receiving 2418 citations. Previous affiliations of Eric J. Allenspach include University of Pennsylvania & University of Chicago.
Papers
More filters
Journal ArticleDOI
MHC class II–dependent basophil–CD4 + T cell interactions promote T H 2 cytokine–dependent immunity
Jacqueline G. Perrigoue,Steven A. Saenz,Mark C. Siracusa,Eric J. Allenspach,Betsy C. Taylor,Paul R. Giacomin,Meera G. Nair,Yurong Du,Colby Zaph,Nico van Rooijen,Michael R. Comeau,Edward J. Pearce,Terri M. Laufer,David Artis +13 more
TL;DR: It is suggested that major histocompatibility complex class II–dependent interactions between basophils and CD4+ T cells promote T helper type 2 cytokine responses and immunity to helminth infection.
Journal ArticleDOI
Notch Signaling in Cancer
TL;DR: This review critically review literature pertaining to the role of Notch signaling in several cancers, and discusses possible therapeutic targets in the Notch pathway.
Journal ArticleDOI
ERM-dependent movement of CD43 defines a novel protein complex distal to the immunological synapse.
Eric J. Allenspach,Patrick Cullinan,Jiankun Tong,Qizhi Tang,Amanda G. Tesciuba,Judy L. Cannon,Stephenie M. Takahashi,Renell Morgan,Janis K. Burkhardt,Anne I. Sperling +9 more
TL;DR: The results indicate that ERM proteins organize a complex distal to the T cell/APC interaction site and provide evidence that full T cell activation may involve removal of inhibitory proteins from the immunological synapse.
Journal ArticleDOI
Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells.
TL;DR: It is shown that antigen processing and presentation by both lymphoid-resident and migratory DCs was required for clonal selection and expansion of CD4(+) T cells after subcutaneous immunization.
Journal ArticleDOI
Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.
Lisa R. Forbes,Tiphanie P. Vogel,Megan A. Cooper,Johana Castro-Wagner,Edith Schussler,Katja G. Weinacht,Ashley Plant,Helen C. Su,Eric J. Allenspach,Mary Slatter,Mario Abinun,Desa Lilic,Charlotte Cunningham-Rundles,Olive S. Eckstein,Peter Olbrich,R. Paul Guillerman,Niraj C. Patel,Yesim Y. Demirdag,Christa S. Zerbe,Alexandra F. Freeman,Steven M. Holland,Paul Szabolcs,Andrew R. Gennery,Troy R. Torgerson,Joshua D. Milner,Jennifer W. Leiding,Jennifer W. Leiding +26 more
TL;DR: Jinibs have been used to treat the severe immune-dysregulation in patients with either STAT1 GOF or STAT3 GOF mutations.